Needham & Company LLC Reaffirms Hold Rating for Omeros (NASDAQ:OMER)

Needham & Company LLC restated their hold rating on shares of Omeros (NASDAQ:OMER - Free Report) in a report released on Friday morning,Benzinga reports.

OMER has been the topic of a number of other research reports. RODMAN&RENSHAW upgraded shares of Omeros to a "strong-buy" rating in a research report on Thursday, November 14th. Rodman & Renshaw began coverage on shares of Omeros in a report on Thursday, November 14th. They set a "buy" rating and a $9.00 price target on the stock. D. Boral Capital reissued a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research note on Thursday. Cantor Fitzgerald restated a "neutral" rating on shares of Omeros in a research report on Thursday, November 14th. Finally, StockNews.com upgraded Omeros from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $22.50.

Omeros Price Performance

Shares of Omeros stock traded up $0.15 on Friday, reaching $9.33. The company had a trading volume of 522,245 shares, compared to its average volume of 1,000,426. The firm has a market cap of $540.67 million, a price-to-earnings ratio of -4.04 and a beta of 2.01. The firm's 50-day moving average price is $9.35 and its two-hundred day moving average price is $6.00. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60.

Hedge Funds Weigh In On Omeros

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP bought a new stake in shares of Omeros in the 3rd quarter valued at about $305,000. Barclays PLC raised its stake in Omeros by 121.3% in the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock worth $376,000 after buying an additional 51,873 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company's stock worth $887,000 after buying an additional 31,081 shares during the period. AQR Capital Management LLC bought a new stake in Omeros during the 2nd quarter valued at $105,000. Finally, SG Americas Securities LLC purchased a new position in shares of Omeros in the 3rd quarter valued at $80,000. 48.79% of the stock is owned by hedge funds and other institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.